Immunovant, Inc. (NASDAQ: IMVT) is a Healthcare company (Biotechnology) with a market capitalization of $6.8B. The Maz Rating grades it against the other companies in its sector.
Immunovant, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $32.80, Immunovant, Inc. trades at 970.7x sales and 10.5x book value. Over the last twelve months it generated about $7M of revenue and a net loss of $522M. It runs an operating margin of -7488.4% and a net margin of -7173.5%. It shows return on equity of -63.0%, return on invested capital of -80.7% and a free cash flow yield of -5.7%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 7.31. Over the past 52 weeks the share price ranged from $21.86 to $45.42, with a beta of 0.84.
Immunovant, Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 18 Buy, 4 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Immunovant, Inc. (IMVT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.1% / 30% · Interest income / Revenue 689700000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.1% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 689700000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.1% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 689700000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 94.3% / 33.33% · Receivables / Avg Assets (4Q) 0.18% / 33.33% · Interest income / Revenue 689700000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 94.9% / 33.33% · (Cash+Recv) / Total Assets 94.9% / 33.33% · Interest income / Revenue 689700000.0% / 5% | Fail |
No. As of September 2026, Immunovant, Inc. (IMVT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Immunovant, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 689700000.0% of each dividend: Immunovant, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q2 2027). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.